ROBERTO HEGG
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina - Docente
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
LIM/58 - Laboratório de Ginecologia Estrutural e Molecular, Hospital das Clínicas, Faculdade de Medicina
15 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 15
- IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab plus chemotherapy in early triple-negative breast cancer (TNBC)(2020) HARBECK, N.; ZHANG, H.; BARRIOS, C. H.; SAJI, S.; JUNG, K. H.; HEGG, R.; KOEHLER, A.; SOHN, J.; IWATA, H.; TELLI, M. L.; FERRARIO, C.; PUNIE, K.; PENAULT-LLORCA, F.; PATEL, S.; DUC, A. Nguyen; LISTE-HERMOSO, M.; MAIYA, V.; MOLINERO, L.; CHUI, S. Y.; MITTENDORF, E.
- Effect of neoadjuvant chemotherapy on low-density lipoprotein (LDL) receptor and LDL receptor-related protein 1 (LRP-1) receptor in locally advanced breast cancer(2012) PIRES, L. A.; HEGG, R.; FREITAS, F. R.; TAVARES, E. R.; ALMEIDA, C. P.; BARACAT, E. C.; MARANHAO, R. C.Low-density lipoprotein (LDL) receptors are overexpressed in most neoplastic cell lines and provide a mechanism for the internalization and concentration of drug-laden nanoemulsions that bind to these receptors. The aim of the present study was to determine whether the administration of standard chemotherapeutic schemes can alter the expression of LDL and LDL receptor-related protein 1 (LRP-1) receptors in breast carcinoma. Fragments of tumoral and normal breast tissue from 16 consecutive volunteer women with breast cancer in stage II or III were obtained from biopsies before the beginning of neoadjuvant chemotherapy and after chemotherapy, from fragments excised during mastectomy. Tissues were analyzed by immunohistochemistry for both receptors. Because complete response to treatment was achieved in 4 patients, only the tumors from 12 were analyzed. Before chemotherapy, there was overexpression of LDL receptor in the tumoral tissue compared to normal breast tissue in 8 of these patients. LRP-1 receptor overexpression was observed in tumors of 4 patients. After chemotherapy, expression of both receptors decreased in the tumors of 6 patients, increased in 4 and was unchanged in 2. Nonetheless, even when chemotherapy reduced receptors expression, the expression was still above normal. The fact that chemotherapy does not impair LDL receptors expression supports the use of drug carrier systems that target neoplastic cells by the LDL receptor endocytic pathway in patients on conventional chemotherapy.
conferenceObject nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, Her2-metastatic breast cancer(2021) HUOBER, J.; HAMILTON, E.; CORTES, J.; OZYILKAN, O.; CHEN, S. C.; PETRAKOVA, K.; MANIKHAS, A.; JERUSALEM, G.; HEGG, R.; CHAPMAN, S.; YANG, Z.; CHEN, Y.; JOHNSTON, E.; MARTIN, M.- nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2-metastatic breast cancer(2020) HAMILTON, E. P.; CORTES, J.; OZYILKAN, O.; CHEN, S-C.; PETRAKOVA, K.; MANIKHAS, A.; JERUSALEM, G.; HEGG, R.; HUOBER, J.; CHAPMAN, S. C.; YANG, Z.; CHEN, Y.; JOHNSTON, E. L.; MARTIN, M.
- Abemaciclib in high risk early breast cancer(2020) JOHNSTON, S.; HARBECK, N.; HEGG, R.; TOI, M.; MARTIN, M.; SHAO, Z.; CAMPONE, M.; HAMILTON, E.; SOHN, J.; GUARNERI, V.; CORTES, J.; NEVEN, P.; BOYLE, F.; SMITH, I.; FRENZEL, M.; HEADLEY, D.; WEI, R.; COX, J.; O'SHAUGHNESSY, J.; RASTOGI, P.
- nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2-advanced breast cancer(2019) HAMILTON, E.; CORTES, J.; DIERAS, V.; OZYILKAN, O.; CHEN, S-C; PETRAKOVA, K.; MANIKHAS, A.; JERUSALEM, G.; HEGG, R.; LU, Y.; BEAR, M. M.; JOHNSTON, E. L.; MARTIN, M.
conferenceObject Safety and efficacy in ROSiA, a single-arm study of extended duration front-line (FL) bevacizumab (BEV)-containing therapy in 1021 women with ovarian cancer (OC)(2015) OZA, A. M.; SELLE, F.; DAVIDENKO, I.; KORACH, J.; MENDIOLA, C.; GOCZE, P.; PAUTIER, P.; CHMIELOWSKA, E.; BAMIAS, A.; DECENSI, A.; ZVIRBULE, Z.; GONZALEZ-MARTIN, A.; HEGG, R.; JOLY, F.; ZAMAGNI, C.; GADDUCCI, A.; DEURLOO, R.; REVIL, C.; ROBB, S.; COLOMBO, N.conferenceObject BIOMARKER (BM) ANALYSES OF A PHASE II STUDY OF NEOADJUVANT PERTUZUMAB AND TRASTUZUMAB WITH AND WITHOUT ANTHRACYCLINE (ATC)-CONTAINING CHEMOTHERAPY FOR TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER (BC) (TRYPHAENA)(2012) SCHNEEWEISS, A.; CHIA, S.; HEGG, R.; TAUSCH, C.; DEB, R.; RATNAYAKE, J.; KIERMAIER, A.; MCNALLY, V.; ROSS, G.; CORTES, J.Background TRYPHAENA showed that concurrent administration of trastuzumab (H) plus pertuzumab (P) with ATC in the neoadjuvant setting resulted in similar cardiac tolerability to sequential administration of ATC or to an ATC-free regimen. In addition, neoadjuvant P with H administered in combination with ATC- or carboplatin-based standard chemotherapy (CT) resulted in high pathological complete response (pCR, [ypT0/is]) rates, regardless of the CT regimen, in patients (pts) with HER2-positive BC. The molecular profile of pts who achieved a pCR was compared with those who did not. Methods Baseline core biopsies and sera from over 90% of the 225 pts enrolled in TRYPHAENA were available for BM analyses. The BMs and methods of assessment included: HER1/2/3, PTEN, and IGF1R protein expression by IHC (and FISH for HER2); HER1/2/3 mRNA expression by qRT-PCR; c-myc and TOP2A by FISH and PCR-based PIK3CA analyses detecting 8 mutations. Potential relationships between BMs and pCR were measured primarily using categorical analysis methods (chi-square test of association and Cochran–Mantel–Haenszel statistic). Median values were used as cut-offs except for TOP2A and PTEN where cut-offs were applied following a biologic rationale. Results Besides HER2 protein levels, no other measured BM was associated with pCR when BM samples from pts in each treatment arm were considered separately. TOP2A amplification (≥ 2.0 ratio) was observed in 32% of pts and was not associated with response to ATC regimen. There is no strong biologic rationale for correlation between BMs and pCR outcomes after treatment with different CT regimens; therefore, data from all pts were pooled. In the combined analysis, HER2 protein levels remained significantly correlated with pCR and high levels of HER2 mRNA were also indicative of improved pCR rates. PIK3CA mutations were seen in 24% of pts and were not associated with pCR. Conclusion This analysis supports the use of HER2 overexpression as the strongest predictive and clinically relevant BM for pCR after treatment with H + P + CT neoadjuvant regimen for pts with HER2-positive BC.- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)(2013) SCHNEEWEISS, A.; CHIA, S.; HICKISH, T.; HARVEY, V.; ENIU, A.; HEGG, R.; TAUSCH, C.; SEO, J. H.; TSAI, Y. -F.; RATNAYAKE, J.; MCNALLY, V.; ROSS, G.; CORTES, J.Pertuzumab (P) combined with trastuzumab (H)-based chemotherapy improves efficacy in early and advanced HER2-positive breast cancer. We assessed the tolerability, with particular focus on cardiac safety, of H and P with chemotherapy in the neoadjuvant treatment of HER2-positive early breast cancer. In this multicenter, open-label phase II study, patients with operable, locally advanced, or inflammatory breast cancer were randomized 1 : 1 : 1 to receive six neoadjuvant cycles q3w (Arm A: 5-fluorouracil, epirubicin, cyclophosphamide [FEC] + H + P x3 -> docetaxel [T] + H + P x3; Arm B: FEC x3 -> T + H + P x3; Arm C: T + carboplatin + H [TCH]+P x6). pCR was assessed at surgery and adjuvant therapy given to complete 1 year of H. Two hundred twenty-five patients were randomized. During neoadjuvant treatment, two patients (2.7%; Arm B) experienced symptomatic left ventricular systolic dysfunction (LVSD) and 11 patients (Arm A: 4 [5.6%]; Arm B: 4 [5.3%]; Arm C: 3 [3.9%]) had declines in left ventricular ejection fraction of >= 10% points from baseline to < 50%. Diarrhea was the most common adverse event. pCR (ypT0/is) was reported for 61.6% (Arm A), 57.3% (Arm B), and 66.2% (Arm C) of patients. The combination of P with H and standard chemotherapy resulted in low rates of symptomatic LVSD.
- IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab plus chemo in early triple-negative breast cancer (TNBC)(2020) SAJI, S.; MITTENDORF, E.; HARBECK, N.; ZHANG, H.; BARRIOS, C. H.; HEGG, R.; KOEHLER, A.; SOHN, J.; IWATA, H.; TELLI, M. L.; FERRARIO, C.; PUNIE, K.; LLORCA, F. Penault; PATEL, S.; DUC, A. Nguyen; HERMOSO, M. Liste; MAIYA, V.; MOLINERO, L.; CHUI, S.; JUNG, K. H.